uniQure (QURE) Common Equity (2015 - 2026)
uniQure (QURE) posted quarterly Common Equity of $324.0 million for Q2 2026, up 8195.18% year-over-year from $3.9 million in Q2 2025, and up 116.98% quarter-over-quarter from $149.3 million in Q1 2026.
Analysis
uniQure (QURE) Common Equity (2015 - 2026) Analysis & Trends
uniQure's Common Equity history runs 12 years deep, the most recent figure standing at $324.0 million for Q2 2026.
- In Q2 2026, Common Equity rose 8195.18% year-over-year to $324.0 million; the TTM figure through Jun 2026 stood at $324.0 million (up 8195.18% YoY), while the FY2025 annual figure was $198.9 million, up 3045.81% from the prior year.
- Common Equity for Q2 2026 stood at $324.0 million, up from $149.3 million in the prior quarter.
- The five-year high for Common Equity was $546.0 million in Q1 2022, with the low at -$6.8 million in Q4 2024.
- The 5-year median for Common Equity is $218.2 million (2023), against an average of $244.2 million.
- The sharpest annual moves came in 2025 and 2026: Common Equity slumped 104.12% in 2025, then soared 8195.18% in 2026.
- uniQure's Common Equity stood at $476.0 million in 2022, then slumped by 56.37% to $207.7 million in 2023, then plunged by 103.25% to -$6.8 million in 2024, then surged by 3045.81% to $198.9 million in 2025, then surged by 62.92% to $324.0 million in 2026.
- Business Quant data shows QURE's Common Equity at $324.0 million in Q2 2026, $149.3 million in Q1 2026, and $198.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 324.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 324.05 Mn |
| Mar 31, 2026 | 149.34 Mn |
| Dec 31, 2025 | 198.90 Mn |
| Sep 30, 2025 | 228.75 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Mar 31, 2025 | 33.69 Mn |
| Dec 31, 2024 | -6.75 Mn |
| Sep 30, 2024 | 55.82 Mn |
| Jun 30, 2024 | 97.11 Mn |
| Mar 31, 2024 | 146.75 Mn |
| Dec 31, 2023 | 207.67 Mn |
| Sep 30, 2023 | 268.78 Mn |
| Jun 30, 2023 | 353.32 Mn |
| Mar 31, 2023 | 412.77 Mn |
| Dec 31, 2022 | 476.01 Mn |
| Sep 30, 2022 | 421.17 Mn |
| Jun 30, 2022 | 486.49 Mn |
| Mar 31, 2022 | 546.00 Mn |
| Dec 31, 2021 | 595.78 Mn |
| Sep 30, 2021 | 590.76 Mn |